Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

178 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R, Egle A, Villunger A. Greil R, et al. Among authors: villunger a. Leuk Lymphoma. 1998 Nov;31(5-6):477-90. doi: 10.3109/10428199809057607. Leuk Lymphoma. 1998. PMID: 9922038 Review.
Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.
Villunger A, Egle A, Kos M, Hittmair A, Maly K, Greil R. Villunger A, et al. Int J Cancer. 1996 Feb 8;65(4):498-505. doi: 10.1002/(SICI)1097-0215(19960208)65:4<498::AID-IJC18>3.0.CO;2-6. Int J Cancer. 1996. PMID: 8621234
2',2'-Difluorodeoxycytidine (gemcitabine) induces apoptosis in myeloma cell lines resistant to steroids and 2-chlorodeoxyadenosine (2-CdA).
Gruber J, Geisen F, Sgonc R, Egle A, Villunger A, Boeck G, Konwalinka G, Greil R. Gruber J, et al. Among authors: villunger a. Stem Cells. 1996 May;14(3):351-62. doi: 10.1002/stem.140351. Stem Cells. 1996. PMID: 8724701
Modulation of Apo-1/Fas (CD95)-induced programmed cell death in myeloma cells by interferon-alpha 2.
Egle A, Villunger A, Kos M, Böck G, Gruber J, Auer B, Greil R. Egle A, et al. Among authors: villunger a. Eur J Immunol. 1996 Dec;26(12):3119-26. doi: 10.1002/eji.1830261244. Eur J Immunol. 1996. PMID: 8977313
The interleukin 1beta-converting enzyme inhibitor CrmA prevents Apo1/Fas- but not glucocorticoid-induced poly(ADP-ribose) polymerase cleavage and apoptosis in lymphoblastic leukemia cells.
Geley S, Hartmann BL, Kapelari K, Egle A, Villunger A, Heidacher D, Greil R, Auer B, Kofler R. Geley S, et al. Among authors: villunger a. FEBS Lett. 1997 Jan 27;402(1):36-40. doi: 10.1016/s0014-5793(96)01496-2. FEBS Lett. 1997. PMID: 9013854
Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: relationship between responsiveness to anti-Fas mab and p53 functional status.
Egle A, Villunger A, Marschitz I, Kos M, Hittmair A, Lukas P, Grünewald K, Greil R. Egle A, et al. Among authors: villunger a. Br J Haematol. 1997 May;97(2):418-28. doi: 10.1046/j.1365-2141.1997.382680.x. Br J Haematol. 1997. PMID: 9163609
Constitutive expression of Fas (Apo-1/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance.
Villunger A, Egle A, Marschitz I, Kos M, Böck G, Ludwig H, Geley S, Kofler R, Greil R. Villunger A, et al. Blood. 1997 Jul 1;90(1):12-20. Blood. 1997. PMID: 9207432
Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
Villunger A, Egle A, Kos M, Hartmann BL, Geley S, Kofler R, Greil R. Villunger A, et al. Cancer Res. 1997 Aug 15;57(16):3331-4. Cancer Res. 1997. PMID: 9269989
Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia.
Tinhofer I, Marschitz I, Kos M, Henn T, Egle A, Villunger A, Greil R. Tinhofer I, et al. Among authors: villunger a. Blood. 1998 Jun 1;91(11):4273-81. Blood. 1998. PMID: 9596676
Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.
Villunger A, Egle A, Kos M, Egle D, Tinhofer I, Henn T, Uberall F, Maly K, Greil R. Villunger A, et al. Br J Haematol. 1998 Sep;102(4):1069-80. doi: 10.1046/j.1365-2141.1998.00880.x. Br J Haematol. 1998. PMID: 9734660
178 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page